SuperworthAlkermes plc. profit margin ALKS
Gross, operating and net profit as a share of revenue over the last twelve months, from 2011.
- Net margin, 12 months
- 4.0%
- Operating margin, 12 months
- 7.0%
- Net margin on a year earlier
- −19.2 pts
- Peer median
- 15.0%
Over the twelve months to Jun 30, 2026, Alkermes plc. kept 4.0% of its revenue as net profit, with an operating margin of 7.0% and a gross margin of 84.6%.
Five years earlier its net margin was −5.7%.
The median for 10 large drugmakers of a similar size is 15.0%.
Profit margin over time
Fiscal year by fiscal year
| Fiscal year | Net margin | Operating margin | Gross margin |
|---|---|---|---|
| FY2025 | 16.4% | 17.2% | 86.7% |
| FY2024 | 23.6% | 27.0% | 84.2% |
| FY2023 | 21.4% | 24.9% | 84.8% |
| FY2022 | −14.2% | −12.8% | 80.4% |
| FY2021 | −4.1% | −2.5% | 83.2% |
| FY2020 | −10.7% | −10.8% | 82.8% |
| FY2019 | −16.8% | −15.0% | 84.6% |
| FY2018 | −12.7% | −9.1% | 83.9% |
| FY2017 | −17.5% | −16.4% | 82.9% |
| FY2016 | −28.0% | −28.0% | 82.3% |
| FY2015 | −36.2% | −35.7% | 77.9% |
| FY2014 | −4.9% | −14.1% | 71.6% |
| FY2013 | 4.3% | 14.2% | 70.4% |
| FY2013 | 3.5% | 5.8% | 69.4% |
| FY2012 | −29.1% | −22.6% | 67.3% |
Quarter by quarter
| Quarter | Ended | Net margin, 12 months | Change on a year | Operating margin |
|---|---|---|---|---|
| Q2 FY26 | 4.0% | −19.2 pts | 7.0% | |
| Q1 FY26 | 9.8% | −13.5 pts | 12.3% | |
| Q4 FY25 | 16.4% | −7.2 pts | 17.2% | |
| Q3 FY25 | 22.3% | +0.1 pts | 23.6% | |
| Q2 FY25 | 23.1% | +4.0 pts | 24.9% | |
| Q1 FY25 | 23.3% | −1.9 pts | 25.8% | |
| Q4 FY24 | 23.6% | +2.2 pts | 27.0% | |
| Q3 FY24 | 22.1% | +8.6 pts | 20.8% | |
| Q2 FY24 | 19.1% | +12.1 pts | 19.7% | |
| Q1 FY24 | 25.2% | +39.8 pts | 27.1% | |
| Q4 FY23 | 21.4% | +35.6 pts | 24.9% | |
| Q3 FY23 | 13.5% | +24.9 pts | 21.3% |
Against its peers
Companies in Drug Manufacturers - General nearest Alkermes plc.'s size, closest first, today.
| Company | Profit margin |
|---|---|
| ALKSAlkermes plc. | 4.0% |
| AMRXAmneal Pharmaceuticals | 5.0% |
| TGTXTG Therapeutics | 55.2% |
| LGNDLigand Pharmaceuticals | 67.9% |
| KNSAKiniksa Pharmaceuticals International | 9.6% |
| PTGXProtagonist Therapeutics | 29.4% |
| CORTCorcept Therapeutics | 6.6% |
| BMRNBiomarin Pharmaceutical | 2.1% |
| INDVIndivior Pharmaceuticals | 26.7% |
| ARQTArcutis Biotherapeutics | 6.1% |
| JAZZJazz Pharmaceuticals | 20.4% |
| Peer median | 15.0% |
Where Alkermes plc. ranks
What the profit margin tells you
Profit as a share of revenue at three levels: gross (after making the product), operating (after running the business) and net (after everything, including tax and interest).
Compare within an industry. 10% is superb for a retailer and poor for a software company.
More on Alkermes plc.
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.